| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | GALT | Common Stock | Award | $19.3K | +9.31K | +1.05% | $2.07 | 896K | Feb 28, 2023 | Direct | F1, F2 |
| transaction | GALT | Common Stock | Tax liability | -$156K | -75.5K | -8.43% | $2.07 | 820K | Mar 1, 2023 | Direct | F2, F3 |
| Id | Content |
|---|---|
| F1 | Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units ("DSUs") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024. |
| F2 | Represents shares underlying DSUs and Common Stock. |
| F3 | Represents shares withheld from issuance to Mr. Lewis for federal and state withholding taxes on income. |